ArticleBMC microbiology2025
Unveiling meropenem resistance and co-resistance patterns in Klebsiella pneumoniae and Acinetobacter baumannii: a global genome analysis using ML/DL and association mining.
Article in BMC microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Molecular and Structural Insights ofAntibiotics (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
The increasing prevalence of meropenem-resistant gram-negative bacteria has led to higher treatment failure and mortality rates. The global availability of bacterial WGS data with antimicrobial resistance phenotypes enables large-scale analyses to explore resistance determinants. This study investigated meropenem resistance mechanisms in multidrug-resistant Klebsiella pneumoniae (KP) and Acinetobacter baumannii (AB) isolates using advanced data analytics. We analysed AMR genes and mutations from 2,411 KP and 375 AB isolates. Notable differences were observed in the proportions of genes contributing to the meropenem resistance mechanism categories between KP and AB, including carbapenemases (4% in KP, 23% in AB), antibiotic efflux (30%, 60%), target alteration (23%, 12%), and reduced permeability (18%, 3%). Mutation frequencies also varied, with antibiotic efflux (26%, 67%), target alteration (64%, 5%), and reduced permeability (7%, 15%). Using ML/DL and association mining approaches, we identified key features such as bla
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.